Forskning ved Københavns Universitet - Københavns Universitet

Forside

Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.
OriginalsprogEngelsk
TidsskriftJournal of Internal Medicine
Vol/bind250
Udgave nummer5
Sider (fra-til)406-14
Antal sider9
ISSN0954-6820
StatusUdgivet - nov. 2001

ID: 92192140